安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- About Us - RAPT Therapeutics
RAPT Therapeutics is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunologic diseases Utilizing our deep and proprietary expertise in immunology, we develop novel molecules that are designed to modulate the critical immune responses underlying these diseases Our
- Homepage - RAPT Therapeutics
RAPT Therapeutics is a clinical-stage biopharmaceutical company driven by our mission to treat inflammatory and immunologic diseases Our cutting-edge science is fully focused on developing therapeutics that intelligently target key drivers of the immune system to transform the treatment of inflammatory and immunologic diseases, and improve and empower countless lives Join us in our quest
- Pipeline - RAPT Therapeutics
RAPT Therapeutics is focused on the development of therapies for patients with significant unmet needs in inflammatory and immunologic diseases Utilizing our deep and proprietary expertise in immunology, we are developing novel molecules that are designed to modulate the critical immune responses underlying these diseases
- RAPT Therapeutics Announces Pricing of Public Offering of Common Stock
In addition, RAPT has granted the underwriters a 30-day option to purchase up to an additional 1,250,000 shares of its common stock at the public offering price, less underwriting discounts and commissions All of the shares of common stock are being offered by RAPT
- Science - RAPT Therapeutics
RPT904 long-acting anti-IgE antibody RPT904 is a novel half-life extended monoclonal antibody (mAb) designed to bind free human immunoglobulin E (IgE), a key driver of allergic diseases We plan to develop RPT904 initially as a treatment for food allergy (FA) and chronic spontaneous urticaria (CSU) and potentially other allergic inflammatory diseases in the future In a first-in-human study in
- RAPT Therapeutics Initiates prestIgE Phase 2b Clinical Trial of . . .
RAPT Therapeutics Initiates prestIgE Phase 2b Clinical Trial of Ozureprubart (RPT904) in Patients with Food Allergies October 27, 2025 Trial initiation in food allergy follows promising results in Phase 2 trial in chronic spontaneous urticaria, another IgE-driven condition RAPT seeks to develop a differentiated anti-IgE therapy for the many patients with food allergies SOUTH SAN FRANCISCO
- RAPT Therapeutics Deepens Expertise in Allergic Diseases with . . .
RAPT Therapeutics is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases
- FLX Bio Announces Name Change to RAPT Therapeutics - RAPT Therapeutics
SOUTH SAN FRANCISCO, Calif --( BUSINESS WIRE )--FLX Bio, a clinical-stage, immunology-based biopharmaceutical company, today announced it has changed its name to RAPT Therapeutics, Inc , to more accurately represent the company’s dedication and focused efforts to develop and commercialize oral
|
|
|